Loading
A phase 3 trial of Cadonilimab in gastric & gastro-oesophageal junction cancer, run by Akeso, now recruiting.
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma is a phase 3 interventional study registered as NCT07023315 by Akeso, with 760 participants planned, started 2025-08-14 and due to reach its primary completion in 2029-07. Interventions recorded: Cadonilimab, SOX chemotherapy and Placebo.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.